報價延遲最少15分鐘:2026/06/03 16:41 EDT
盤後時段
|
||||
|
58.76 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
58.76
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.11/2.88
|
|
企業價值
2.54B
|
| 資產負債 |
|
每股賬面淨值
8.11
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
182.95M
|
|
每股收益
0.29
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction. |
